A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers

Phase 1

Completed

• Conditions: Type II Diabetes Mellitus
• Interventions: Drug: HMS5552; Drug: Placebo

• Registration Number: NCT01952535
• Lead Sponsor: Hua Medicine Limited

Brief Summary

The objectives of this study is to determine the safety profiles, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy adult subjects.

Detailed Description

This will be a randomized, double-blind and placebo-controlled safety study with single oral doses of HMS5552 given to healthy volunteers.

The primary objective is to characterize the safety profiles of HMS5552 following single ascending doses (SAD) in healthy adult subjects.

The secondary objectives include:

1. To assess the pharmacokinetic profiles of HMS5552 after single dosing

2. To assess the preliminary pharmacodynamic profiles of HMS5552

Each study subject will receive a single oral dose of HMS5552. During each dosing, eight subjects will be allocated to receive HMS5552 and two subjects will be allocated to receive placebo treatment.

Several doses of HMS5552 will be tested. Dose titration or reduction is determined for each cohort based on the safety and pharmacokinetic data obtained from the lower dose cohorts.

Study Timeline

• Study Start: 2013-09
• Study First Submitted: 2013-09-22
• Study First Submitted QC: 2013-09-24
• Study First Posted: 2013-09-30
• Primary Completion: 2013-12
• Study Completion: 2013-12
• Status Verified: 2017-11
• Last Update Submitted: 2017-11-17
• Last Update Posted: 2017-11-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Female and male volunteers, 18 to 45 years of age
• BMI: 18 to 24 kg/m2
• Fasting plasma glucose: 3.9 to 6.1 mmol/L
• Glucose level at 2 hours following oral glucose tolerance test <7.8 mmol/L
• HbA1c: 4 to 6.5%
• Normal supine blood pressure and normal ECG recordings

Exclusion Criteria

• Female with child-bearing potential
• Evidence of clinically-significant renal, cardiac, bronchopulmonary, vascular, gastrointestinal, allergic, neurologic, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, cancer, hepatitis or cirrhosis.
• Intake of grapefruit or anything that may affect liver enzyme function within 1 month prior to the dosing day
• Clinically-relevant deviation from normal in the physical examination
• Subjects with a medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HMS5552 dose 5	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 6	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 1	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 2	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 3	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 2	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 4	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 4	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 1	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 3	Placebo	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 6	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.
HMS5552 dose 5	HMS5552	A single dose of HMS5552 tablets (5\~50mg) taken orally.

Primary Outcome Measures

Name	Time	Method
Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.	up to 72 hours post-dose

Secondary Outcome Measures

Name	Time	Method
The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf, AUC0-t, Cmax, Tmax, Ae, T1/2.	up to 72 hours post-dose	Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose. Urine will be collected at predose, 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, and 48 to 72 hour post-dose.
Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level	up to 6 hours post-dose

Trial Locations

Locations (1)

Hua Medicine Limited; 🇨🇳 Shanghai, Shanghai, China